The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Azopt     (2S)-2-ethylamino-4-(3- methoxypropyl)-5,5...

Synonyms: Birnzolamide, Brinzolamide, SureCN24636, CHEMBL220491, CHEBI:3176, ...


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.


Disease relevance of Brinzolamide


High impact information on Brinzolamide


Chemical compound and disease context of Brinzolamide


Biological context of Brinzolamide


Anatomical context of Brinzolamide


Associations of Brinzolamide with other chemical compounds


Gene context of Brinzolamide


Analytical, diagnostic and therapeutic context of Brinzolamide


  1. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Sugrue, M.F. Progress in retinal and eye research. (2000) [Pubmed]
  2. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Sall, K. Survey of ophthalmology. (2000) [Pubmed]
  3. Topical brinzolamide and metabolic acidosis. Menon, G.J., Vernon, S.A. The British journal of ophthalmology. (2006) [Pubmed]
  4. Corneal edema in glaucoma patients after the addition of brinzolamide 1% ophthalmic suspension. Tanimura, H., Minamoto, A., Narai, A., Hirayama, T., Suzuki, M., Mishima, H.K. Jpn. J. Ophthalmol. (2005) [Pubmed]
  5. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Hollo, G., Chiselita, D., Petkova, N., Cvenkel, B., Liehneova, I., Izgi, B., Berta, A., Szaflik, J., Turacli, E., Stewart, W.C. European journal of ophthalmology (2006) [Pubmed]
  6. Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. Nishimori, I., Minakuchi, T., Onishi, S., Vullo, D., Scozzafava, A., Supuran, C.T. J. Med. Chem. (2007) [Pubmed]
  7. Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination. Stams, T., Chen, Y., Boriack-Sjodin, P.A., Hurt, J.D., Liao, J., May, J.A., Dean, T., Laipis, P., Silverman, D.N., Christianson, D.W. Protein Sci. (1998) [Pubmed]
  8. Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy. Unal, M., Yücel, I., Akar, Y. Journal of cataract and refractive surgery. (2006) [Pubmed]
  9. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Reis, R., Queiroz, C.F., Santos, L.C., Avila, M.P., Magacho, L. Clinical therapeutics. (2006) [Pubmed]
  10. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Shin, D. Survey of ophthalmology. (2000) [Pubmed]
  11. Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with openangle glaucoma or ocular hypertension. Franks, W. Current medical research and opinion. (2006) [Pubmed]
  12. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Shoji, N., Ogata, H., Suyama, H., Ishikawa, H., Suzuki, H., Morita, T., Kawai, H., Nishimoto, H., Nemoto, T., Shimizu, K. Current medical research and opinion. (2005) [Pubmed]
  13. Structural analysis of inhibitor binding to human carbonic anhydrase II. Boriack-Sjodin, P.A., Zeitlin, S., Chen, H.H., Crenshaw, L., Gross, S., Dantanarayana, A., Delgado, P., May, J.A., Dean, T., Christianson, D.W. Protein Sci. (1998) [Pubmed]
  14. Increased optic nerve head blood flow after 1 week of twice daily topical brinzolamide treatment in Dutch-belted rabbits. Barnes, G.E., Li, B., Dean, T., Chandler, M.L. Survey of ophthalmology. (2000) [Pubmed]
  15. Preclinical overview of brinzolamide. DeSantis, L. Survey of ophthalmology. (2000) [Pubmed]
  16. Effects of brinzolamide on ocular haemodynamics in healthy volunteers. Kaup, M., Plange, N., Niegel, M., Remky, A., Arend, O. The British journal of ophthalmology. (2004) [Pubmed]
  17. Cellular cytotoxicity of antiglaucoma drugs in cultured corneal endothelial cells. Wu, K.Y., Wang, H.Z., Hong, S.J. Kaohsiung J. Med. Sci. (2007) [Pubmed]
  18. Medical control of intraocular pressure after phacoemulsification. Dayanir, V., Ozcura, F., Kir, E., Topaloğlu, A., Ozkan, S.B., Aktunç, T. Journal of cataract and refractive surgery. (2005) [Pubmed]
  19. Effect of topical brinzolamide 1% and brimonidine 0.2% on intraocular pressure after phacoemulsification. Cetinkaya, A., Akman, A., Akova, Y.A. Journal of cataract and refractive surgery. (2004) [Pubmed]
  20. Comparing the effects of travoprost and brinzolamide on intraocular pressure after phacoemulsification. Ermis, S.S., Ozturk, F., Inan, U.U. Eye (London, England) (2005) [Pubmed]
  21. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Michaud, J.E., Friren, B. Am. J. Ophthalmol. (2001) [Pubmed]
  22. Cost considerations of medical therapy for glaucoma. Fiscella, R.G., Geller, J.L., Gryz, L.L., Wilensky, J., Viana, M. Am. J. Ophthalmol. (1999) [Pubmed]
  23. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Vullo, D., Franchi, M., Gallori, E., Pastorek, J., Scozzafava, A., Pastorekova, S., Supuran, C.T. Bioorg. Med. Chem. Lett. (2003) [Pubmed]
  24. Effects of brinzolamide on aqueous humor dynamics in monkeys and rabbits. Toris, C.B., Zhan, G.L., McLaughlin, M.A. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2003) [Pubmed]
WikiGenes - Universities